Lipid lowering potential and potentiation effect of curcumin and atorvastatin in-patient with hyperlipidemia

Hyperlipidemiais a term that refers to any of several acquired or genetic disorders that result in a high level of circulating lipids (fats, cholesterol and triglycerides). The condition can affect one fat protein or several. Most people will have no symptoms, with increasing the risk of developing heart problem. It has been found that oxidation processes play important role in developing lipids disorders. Curcumin is a phytochemical antioxidant substance may play a role in lowering lipids levels in the blood.This study was conducted to evaluate the lipid lowering effect of curcumin in Iraqi patients with hyperlipidemia and to study the potentiation effect on atorvastatin.From thosepatients who attendedMedical Clinic in Al-Diwanyiah Teaching Hospital,48 patients of 45-65 years old with diagnosed hyperlipidemia were enrolled in this study,they were divided randomlyinto four groups,12 patients in each. Base line assessment was done in form oflipid profile. 1stgroup was considered as placebo,2ndgroups received atorvastatin,3rd group received curcumin and 4th group received atorvastatin + curcumin. Reassessment was done after 2 months.Curcumin group shows significant reduction in TG (P ≤ o.o5), significant reduction of LDL in atorvastatin group (P≤ 0.05) and highly significant reduction in LDL,TG,and significant reduction in TC in patients received both atorvastatin + curcumin,with no significanteffects on HDL in all treated groups,compared to placebo.curcumin express lipid lowering activity and potentiate atorvastatin action in patient with hyperlipidemia.

Download Full-text

A comparative study of atorvastatin and rosuvastatin on lipid lowering efficacy in hyperlipidemic patients

Bangabandhu Sheikh Mujib Medical University Journal ◽

10.3329/bsmmuj.v11i1.35244 ◽

2018 ◽

Vol 11 (1) ◽

pp. 17

Author(s):

Samia Haque Tonu ◽

Zesmin Fauzia Dewan ◽

Nargis Akhter ◽

Sajal Krishna Banerjee

Keyword(s):

Lipid Profile ◽

Serum Triglyceride ◽

Lipid Lowering ◽

Serum Triglyceride Level ◽

Intergroup Difference ◽

Atorvastatin Group ◽

Significant Difference ◽

Rosuvastatin Group ◽

Significant Change ◽

Lipid Lowering Effect

<p class="Abstract">The aim of the present study was to compare the lipid lowering effect of atorvastatin and rosuvastatin in patients (n=52) with hyperlipidemia. Patients were assigned to atorvastatin 10 mg or rosuvastatin 5 mg daily for 8 weeks. The blood was collected at baseline and after intervention to measure serum lipid profile. The level of serum total cholesterol in both atorvastatin and rosuvastatin groups was significantly reduced after intervention (p<0.00001 and p<0.00001 respectively) but no statistically significant difference (p=0.503) was observed between the two statin-treated groups. The reduction of serum triglyceride level was also significant (p=0.046 in atorvastatin group and p=0.0006 in rosuvastatin group). No significant difference was observed between the two groups (p=0.312). The serum LDL-C level was reduced significantly in both atorvastatin group (p<0.00001) and rosuvastatin group (p<0.00001). Again no statistically significant difference (p= 0.749) was observed between the two groups. No significant change was observed in the serum HDL level. Intergroup difference was not significant (p= 0.721). The present study indicates that, both atorvastatin and rosuvastatin improve the lipid profile but no significant change was observed between the two groups.</p>

Download Full-text

Effect of lipid-lowering activity of the natural original enzyme preparation in the experiment

Biomeditsinskaya Khimiya ◽

10.18097/pbmc20196503227 ◽

2019 ◽

Vol 65 (3) ◽

pp. 227-230

Author(s):

N.N. Klyueva ◽

I.V. Okunevich ◽

N.S. Parfenova ◽

E.V. Belova ◽

E.V. Ageeva

Keyword(s):

Experimental Study ◽

Enzyme Preparation ◽

Cholesterol Oxidase ◽

Lipid Lowering ◽

Good Tolerability ◽

Microbial Enzyme ◽

Low Toxicity ◽

Lowering Activity ◽

Lipid Lowering Effect

The experimental study in vivo was aimed at evaluation of hypolipidemic action of the original natural microbial enzyme preparation of cholesterol oxidase (CHO). In preliminary chronic experiments in rats, rabbits, dogs, low toxicity, good tolerability, and anti-atherosclerotic activity of the CHO preparation were established. To assess the effect of CHO under conditions of moderate, nutritional, atherogenic dyslipoproteinemia, experiments were carried out in rats, guinea pigs, and rabbits. It was shown that administration of CHO had the pronounced lipid-lowering effect in models of atherogenic dyslipoproteinemia induced in these animals.

Download Full-text

W14.378 CETP and MDR1 SNP-haplotypes are associated with lipid lowering effect of fluvastatin in familial hypercholesterolemia

Atherosclerosis ◽

10.1016/s0021-9150(04)90377-2 ◽

2004 ◽

Vol 5 (1) ◽

pp. 87

Author(s):

V MEINER

Keyword(s):

Familial Hypercholesterolemia ◽

Lipid Lowering ◽

Lowering Effect ◽

Lipid Lowering Effect

Download Full-text

W01.11 Non-lipid lowering effect of statins: Inhibition of human aortic vascular smooth muscle cell (VSMC) migration

Atherosclerosis ◽

10.1016/s0021-9150(04)90011-1 ◽

2004 ◽

Vol 5 (1) ◽

pp. 3

Author(s):

M CAMPBELL

Keyword(s):

Smooth Muscle ◽

Vascular Smooth Muscle ◽

Smooth Muscle Cell ◽

Muscle Cell ◽

Vascular Smooth Muscle Cell ◽

Lipid Lowering ◽

Lowering Effect ◽

Lipid Lowering Effect

Download Full-text

Evaluation of Glucose and Lipid Lowering Activity of Arganimide A in Normal and Streptozotocin-Induced Diabetic Rats

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530318666181113124727 ◽

2019 ◽

Vol 19 (4) ◽

pp. 503-510 ◽

Cited By ~ 2

Author(s):

Mohamed Eddouks ◽

Farid Khallouki ◽

Robert W. Owen ◽

Morad Hebi ◽

Remy Burcelin

Keyword(s):

Body Weight ◽

Blood Glucose ◽

Oral Administration ◽

Lipid Profile ◽

Plasma Cholesterol ◽

Diabetic Rats ◽

Lipid Lowering ◽

Glucose Levels ◽

Blood Glucose Levels ◽

Lowering Activity

Aims: Arganimide A (4,4-dihydroxy-3,3-imino-di-benzoic acid) is a compound belonging to a family of aminophenolics found in fruit of Argania spinosa. The purpose of this study was to investigate the glucose and lipid lowering activity of Arganimide A (ARG A). Methods: The effect of a single dose and daily oral administration of Arganimide A (ARG A) on blood glucose levels and plasma lipid profile was tested in normal and streptozotocin (STZ) diabetic rats at a dose of 2 mg/kg body weight. Results: Single oral administration of ARG A reduced blood glucose levels from 26.50±0.61 mmol/L to 14.27±0.73 mmol/L (p<0.0001) six hours after administration in STZ diabetic rats. Furthermore, blood glucose levels were decreased from 5.35±0.30 mmol/L to 3.57±0.17 mmol/L (p<0.0001) and from 26.50±0.61 mmol/L to 3.67±0.29 mmol/L (p<0.0001) in normal and STZ diabetic rats, respectively, after seven days of treatment. Moreover, no significant changes in body weight in normal and STZ rats were shown. According to the lipid profile, the plasma triglycerides levels were decreased significantly in diabetic rats after seven days of ARG treatment (p<0.05). Moreover, seven days of ARG A treatment decreased significantly the plasma cholesterol concentrations (p<0.001). Conclusion: ARG A possesses glucose and lipid-lowering activity in diabetic rats and this natural compound may be beneficial in the treatment of diabetes.

Download Full-text